modelErdafitinib

Diagram of Erdafitinib

Extends from Pharmacolibrary.Drugs.ATC.L.L01EN01.

Information

name:Erdafitinib
ATC code:L01EN01
route:oral
compartments:2
dosage:8mg
volume of distribution:173L
clearance:0.362L/h
other parameters in model implementation

Erdafitinib is an oral, selective pan-fibroblast growth factor receptor (FGFR) inhibitor used in the treatment of urothelial carcinoma with susceptible FGFR genetic alterations. It is approved for use in adults with locally advanced or metastatic urothelial carcinoma for whom other treatment options have failed.

Pharmacokinetics

Pharmacokinetic parameters reported for adult cancer patients (urothelial carcinoma); data mainly from phase I/II studies.

References

  1. Dosne, AG, et al., & Perez-Ruixo, JJ (2020). Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies. Journal of clinical pharmacology 60(4) 515–527. DOI:10.1002/jcph.1547 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31742712

  2. Park, JO, et al., & Sweiti, H (2024). Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial. BMC cancer 24(1) 1006–None. DOI:10.1186/s12885-024-12584-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39138436

  3. Li, LY, et al., & Ouellet, D (2020). Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis. Journal of clinical pharmacology 60(3) 391–399. DOI:10.1002/jcph.1529 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31602692

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)